Catalyst Pharmaceuticals (CPRX) Change in Receivables (2019 - 2026)

Catalyst Pharmaceuticals' Change in Receivables history runs 8 years deep, the most recent figure standing at $4.4 million for Q1 2026.

• Quarterly Change in Receivables fell 24.74% year-over-year to $4.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $59.6 million (up 453.0% YoY) and the FY2025 annual result came in at $61.0 million, up 409.96% from the prior year.
• Change in Receivables was $4.4 million for Q1 2026 at Catalyst Pharmaceuticals, down from $20.1 million in the prior quarter.
• Across five years, Change in Receivables topped out at $40.5 million in Q3 2025 and bottomed at -$5.4 million in Q2 2025.
• A 5-year average of $7.3 million and a median of $5.3 million in 2023 frame the typical range for Change in Receivables.
• Peak annual rise in Change in Receivables reached 18466.67% in 2022, while the deepest fall reached 239.65% in 2022.
• Catalyst Pharmaceuticals' Change in Receivables stood at $1.1 million in 2022, then surged by 395.92% to $5.5 million in 2023, then jumped by 31.93% to $7.2 million in 2024, then surged by 178.34% to $20.1 million in 2025, then slumped by 78.29% to $4.4 million in 2026.
• Business Quant data shows CPRX's Change in Receivables at $4.4 million in Q1 2026, $20.1 million in Q4 2025, and $40.5 million in Q3 2025.